Key result
Nitric oxide-cGMP pathway modulators offer broad therapeutic utility across cardiovascular diseases.
Why the study?
A comprehensive overview of agents modulating the L-arginine:NO:cGMP pathway and their pharmacological profiles in cardiovascular therapy is needed.
This review provides a comprehensive overview of the pharmacological profiles and therapeutic applications of drugs targeting the nitric oxide pathway, primarily in cardiovascular diseases.
Reinforces established cardiovascular use of pathway modulators; leaves open broader therapeutic exploration.
Nitric oxide (NO) is a relatively novel messenger that plays a significant role in a wide range of physiological processes. Currently, it is known that, both, lack and excess of NO can cause diseases, thus a lot of substances have been discovered and utilized which can change the concentration of this molecule within the organism. The aim of the present work is to provide an overview of currently used agents modulating the L-arginine:NO:cGMP pathway, as well as to summarize current understanding of their pharmacological profiles. Nowadays, most of these agents are employed particularly in the treatment of cardiovascular diseases. Further studies can hold promise for enhancing the therapeutic equipment for a variety of other impairments, such as osteoporosis, and also in treatments of the central nervous system.
No takes yet. Share an insight, caveat, or question.
Polakowska et al. (2016) conducted a review in Cardiovascular diseases, erectile dysfunction, pulmonary hypertension, septic shock, osteoporosis. Drugs modulating the L-arginine:NO:cGMP pathway was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: